Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.

@article{Arlen2012ProstateCV,
  title={Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.},
  author={Philip M. Arlen and Lauren V. Wood},
  journal={Expert review of vaccines},
  year={2012},
  volume={11 3},
  pages={287-302}
}
The focus of extensive research in the area of prostate cancer vaccines has led to the approval of the first therapeutic vaccine by the US FDA, sipuleucel-T. As our understanding of immunotherapy has increased, novel approaches have been investigated that have shown considerable promise. As the field has continued to evolve, questions have arisen regarding the potential role of immunotherapy: which populations of patients are most likely to benefit from immunotherapy and how and when should… CONTINUE READING